Page 1

EX - 99.1 2 gkos - 20210805xex99d1.htm EX - 99.1 GLAUKOS FOR IMMEDIATE RELEASE Contact : Chris Lewis Sr. Director , Investor Relations & Corporate Strategy & Development ( 949 ) 481-0510 clewis@glaukos.com Exhibit 99.1 Glaukos Corporation Announces Second Quarter 2021 Financial Results San Clemente , CA - August 5 , 2021 - Glaukos Corporation ( NYSE : GKOS ) , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma , corneal disorders and retinal diseases , today announced financial results for the second quarter ended June 30 , 2021. Key highlights include : • Net sales growth of 147 % to $ 78.1 million in Q2 2021 , compared to $ 31.6 million in Q2 2020 . • Glaucoma net sales of $ 62.7 million and Corneal Health net sales of $ 15.4 million in Q2 2021 . • Gross margin of approximately 77 % and non - GAAP gross margin of approximately 84 % in Q2 2021 . • Operating expenses of $ 74.6 million and non - GAAP operating expenses of $ 67.8 million in Q2 2021 . " We are pleased with our record second quarter financial performance driven by sound execution on our key strategic priorities and the ongoing market recovery , " said Thomas Burns , Glaukos president and chief executive officer . " We remain steadfastly dedicated to transform the treatment of chronic eye diseases for the benefit of patients worldwide . " Second Quarter 2021 Financial Results Net sales increased 147 % in the second quarter of 2021 to $ 78.1 million , compared to $ 31.6 million in the same period in 2020 . Gross margin for the second quarter of 2021 was approximately 77 % , compared to approximately 31 % in the same period in 2020. Non - GAAP gross margin for the second quarter of 2021 was approximately 84 % , compared to approximately 78 % in the same period in 2020 . Selling , general and administrative ( SG & A ) expenses for the second quarter of 2021 increased 19 % to $ 45.3 million , compared to $ 38.1 million in the same period in 2020. Non - GAAP SG & A expenses for the second quarter of 2021 increased 30 % to $ 43.6 million , compared to $ 33.6 million in the same period in 2020 . Research and development ( R & D ) expenses for the second quarter of 2021 increased 28 % to $ 24.3 million , compared to $ 19.0 million in the same period in 2020. Non - GAAP R & D expenses for the second quarter of 2021 increased 29 % to $ 24.1 million , compared to $ 18.6 million in the same period in 2020. In addition , during the second quarter of 2021 , the company also incurred a $ 5.0 million in - process R & D charge associated with an upfront payment related